FDA Aims For Flexibility In Upcoming Drug/Test Co-Development Guidance
This article was originally published in The Gray Sheet
Executive Summary
FDA is trying to build flexibility into its drug/diagnostic co-development guidance to address variability in how and when therapeutics and companion diagnostics are developed
You may also be interested in...
FDA Plans Guidance This Year On Co-Development Of Diagnostics And Drugs
FDA expects to complete a guidance document on co-development of diagnostics and drugs used for personalized medicine by the end of this year, FDA Commissioner Margaret Hamburg said at a meeting in Washington, D.C., Feb. 25
MedCAC Supports Some PGx Test Regimens, But Calls For Overall Better Data
There is enough strong evidence to show that a select few pharmacogenomic (PGx) tests can be applied in a manner that positively affects patient outcomes, members of a CMS advisory panel concluded Jan. 27
Dx Groups To FDA: Time For Companion Diagnostics Guidance Is Now
Industry groups representing test manufacturers, labs, drug firms and others are redoubling their pressure on FDA to clarify the regulatory requirements for co-development of diagnostics and drug treatments